拜瑞妥（Xarelto）于今年7月被FDA批准用于预防膝关节或髋关节置换术患者血栓形成。FDA对拜瑞妥关于出血风险的考虑令该药获批时间推迟了近2年。
基于776个网页-相关网页
利伐沙班（Xarelto）是一种针对患者..
基于506个网页-相关网页
瑞妥(Xarelto)用于 治疗 急性冠脉综合征年都将面临 生物 类似药的瞄准新兴市场和 生物 仿制药等抗癌药Stivarga和 治疗 肺动脉高压药物占据了美...
基于8个网页-相关网页
The safety and effectiveness of Xarelto for the new indications were evaluated in three clinical studies.
FORBES: Rivaroxaban Gains FDA Indications For The Treatment And Prevention Of DVT And PE
The major side effect observed with Xarelto is bleeding, similar to other anti-clotting drugs.
Results showed Xarelto was as effective as the enoxaparin and VKA combination for treating DVT and PE.
应用推荐
模块上移
模块下移
不移动